China Biologic Products (CBPO -4.6%) slips after announcing earlier today that construction of a new production facility at its Guizhou Taibang subsidiary could be delayed due to slower-than-expected government approval of land use rights. The Company says it's working closely with local authorities to secure approval as soon as possible and will provide an update as soon as possible. CBPO had planned to commence work on the project in late 2012, with completion by mid-2014.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs